AptarGroup (ATR) Q2 FY26 earnings call

AptarGroup delivered Q2 FY26 adjusted EPS above guidance, primarily due to strong Pharma segment performance, particularly in injectables and consumer healthcare, offsetting anticipated declines in emergency medicine. While all segments achieved positive sales growth, profitability was pressured by unfavorable product mix and operational challenges in Beauty and Closures, which are expected to progressively improve. The company remains confident in its long-term growth prospects, focusing on disciplined execution and strategic resource allocation under new leadership.